Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
Posted on 20 Mar 2024
Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents. This MoU aims to create synergy in research and development and market exploration by combining the techniques and marketing capabilities of Samsung Medison and Bracco Imaging. Both companies are considering collaborative research to develop protocols for high-frequency and super-resolution imaging for diagnostic purposes. Samsung Medison is among the world's leading manufacturers of innovative premium ultrasound diagnostic equipment while Bracco Imaging is an innovative global leader delivering end-to-end products and solutions through a comprehensive portfolio that includes precision diagnostic imaging modalities. The two companies are considering collaborative research to develop protocols for high-frequency and super-resolution imaging for diagnostic purposes.
This agreement will also focus on global marketing activities including educating healthcare providers, jointly participating in strategic events, and exploring the possibilities in ultrasound-targeted contrast-enhanced drug delivery technologies in association with pharmaceutical agents. Samsung Medison and Bracco Imaging will collaborate on research to diversify the use of ultrasound contrast agents and enhance image resolution in various settings and specialties. Both companies aim to translate device features into diagnostic and clinical benefits for users and patients, including workflow. Bracco Imaging will integrate its quantitative diagnostic analysis software with Samsung Medison's diagnostic ultrasound equipment to improve image reporting and convenience for medical staff.
"Through this MoU agreement with Bracco and global collaboration, we will strengthen our capability in diagnostic ultrasound field, and create an opportunity to enter future ultrasound treatment field," said Yongkwan Kim, CEO of Samsung Medison. "We are planning to increase diagnostic accuracy and expand applicable scope based on Samsung Medison's various ultrasound clinical application techniques and AI solutions."
"It is truly exciting to usher in a new era of contrast agent utilization through our collaboration with Samsung Medison," added Fulvio Renoldi Bracco, CEO of Bracco Imaging. "I am optimistic that this agreement will lead to groundbreaking technological advances in practical treatment applications that will benefit our patients."
